ATOMIC-AHF: Cautious optimism for potential inotrope replacement in acute HF

It didn't meet its primary endpoint, but the randomized phase-2 study of the cardiac myosin activator omecamtiv mecarbil pinpointed a dosage that significantly improved patients' dyspnea, at least in a prespecified subgroup analysis

Source: theHeart.org - September 4, 2013 Category: Cardiology Source Type: news